Earlier this week, the European Commission announced that the Covid-19 vaccine, developed as part of a collaboration between ...

The European Medicines Agency (EMA) will meet on the same day and is due to draw conclusions ... of the vaccine, with fewer than 40 cases of blood clots reported as of last week, AstraZeneca ...

The most important cases, where technology transfer was most extensive, both involved AstraZeneca, which undertook two partnerships in the region (to produce the COVID-19 vaccine that was developed by ...

AstraZeneca made headlines on Tuesday as it initiated the global withdrawal of its COVID-19 vaccine. This decision comes weeks after the pharmaceutical giant acknowledged the vaccine's potential ...

On April 30, AstraZeneca admitted that the vaccine, sold under the name Vaxzevria, can cause fatal blood clots and low platelet counts, also known as thrombosis syndrome with thrombocytopenia ...

The diplomatic row that broke out last week over the supply of AstraZeneca’s vaccine to Europe appears to have cooled after the UK pharma agreed to supply an extra nine million doses.

“At the current time, the use of the Pfizer vaccine is preferred over the AstraZeneca vaccine in adults aged less than 50 years who have not already received a first dose of AstraZeneca vaccin ...

There is no evidence the AstraZeneca Covid vaccine causes blood clots ... EMA executive director, Emer Cooke, said: "Drawing attention to these possible rare conditions and providing information ...

Doctors draw a distinction between a third vaccine dose and a ... Even if you previously had the Oxford/AstraZeneca vaccine, the third dose or booster dose(s) should be of the Pfizer or Moderna ...

A Covid vaccine compensation scheme could be set up after thousands claimed they have been left disabled as a result of the AstraZeneca jab, The Telegraph has learnt. The Health Secretary is ...

However, pregnant women can have the RSV vaccine at the same time as the Covid jab. AstraZeneca pulled its Covid vaccine worldwide because of the surplus of updated vaccines from its competitors.

In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2 billion. However many analysts felt the company had paid far too much ...